The emerging role of sST2 blocking in the therapy of graft-versus-host disease

Yifan Xiao, Fang Zheng

Abstract

Suppression of tumorigenicity 2 (ST2) is an interleukin-1 (IL-1) receptor family member with transmembrane (mST2) and soluble isoforms (sST2) (1).